178.94
+3.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Repligen
From its filings with the US Securities and Exchange Commission
Repligen is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RGEN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $738.3m and net income of $48.9m. At that date it held total assets of $2.95bn and shareholders' equity of $2.11bn.
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies (“mAbs”) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies (“C>”) – that are improving human health worldwide.
We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. Building on over 40 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and commercial leverage) and targeted acquisitions.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Apr 1986
- Employees
- 2,000
- Website
- repligen.com ↗
- Head office
- 41 SEYON STREET, WALTHAM, MA, 02453
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Tony HuntExecutive Chairman of the Board, since 2014$20.3m
- Mr. Olivier LoeillotPresident, Chief Executive Officer, Director, since 2023$7.2m
- Mr. Jason GarlandChief Financial Officer$2.1m
- Mr. James BylundChief Operating Officer$4.2m
- Mr. Ralf KuriyelSenior Vice President - Research and Development$2.0m
- Ms. Karen DawesLead Independent Director, since 2005$428,399
- Mr. Nicolas BarthelemyIndependent Director$324,984
- Dr. Konstantin KonstantinovIndependent Director$301,651
- Dr. Martin MadausIndependent Director$316,984
- Ms. Carrie MannerIndependent Director$306,651
- Mr. Rohin MhatreIndependent Director$306,651
- Mr. Glenn MuirIndependent Director$338,318
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 86
- Environment
- 70
- Social
- 95
- Governance
- 93
- Direct emissions (scope 1)
- 598 t
- Energy emissions (scope 2)
- 2,653 t
- Women in the workforce
- 37%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Repligen Corp benefits from a diversified product portfolio, offering a range of high-quality bioprocessing products and technologies.
- The company has successfully established strategic partnerships with industry leaders, allowing for increased market reach and access to new customers.
- Repligen Corp demonstrates strong research and development capabilities, continually innovating to meet the evolving needs of the bioprocessing industry.
Weaknesses
- The company's revenue is heavily reliant on a few major customers, posing a risk if any of these customers reduce their purchases or switch to competitors.
- Repligen Corp operates in a highly regulated industry, facing challenges in ensuring compliance with various governmental regulations and standards.
Opportunities
- The rapidly growing biopharmaceutical market presents significant opportunities for Repligen Corp to expand its customer base and increase revenue.
- Advancements in bioprocessing technologies open doors for the development of new products and services, allowing Repligen Corp to stay competitive and meet future industry demands.
Threats
- The bioprocessing industry is highly competitive, with the presence of both well-established companies and emerging players, potentially leading to price pressures and market share challenges for Repligen Corp.
- Global economic conditions and fluctuations may impact the demand for bioprocessing products, potentially affecting Repligen Corp's sales and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.